Novartis AG
ORAL FORMULATIONS OF BRANAPLAM

Abstract:

The present invention relates to pharmaceutical compositions suitable for oral administration comprising 5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazi- n-3-yl)phenol (branaplam) and a pharmaceutically acceptable cyclodextrin.